Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 single-arm study of ALXN1840 in adults with Wilson disease assessing liver copper concentration and histopathologic changes over 48 weeks plus extension
2019-003711-60Phase 2Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jun 2020
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-blind, single-arm trial of atn-224 in Wilson disease (WD), sponsored by Alexion Pharmaceuticals. Primary endpoint: Change from baseline to Week 48 in liver copper concentration. Started Jun 2020; status: completed.
02
Drugs
atn-224
03
Conditions
Wilson disease (WD)
Beyond the preview
Go deeper on 2019-003711-60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003711-60.